CD274 and non-small cell lung carcinoma: In the phase III randomized trial named PEARLS/KEYNOTE-091, the investigators randomized 1177 patients with resected stage IB-IIIA NSCLC with any level of PD-L1 expression, including <1%, to receive pembrolizumab at the dose of 200 mg or a placebo every 21 days for a maximum of 18 cycles unless progressive disease or excessive toxicity occurred [25].